Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
During the past 13 years, the highest Debt-to-Equity Ratio of Creative Medical Technology Holdings was -0.02. The lowest was -7.56. And the median was -0.27.
CELZ's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.15 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Creative Medical Technology Holdings Debt-to-Equity Related Terms
Creative Medical Technology Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings Debt-to-Equity Chart
CELZ vs MLEC, DRMA, CURX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Creative Medical Technology Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Creative Medical Technology Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings (CELZ) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Creative Medical Technology Holdings and its competitors. According to the industry distribution chart, Creative Medical Technology Holdings ranks #999999 out of 965 companies in the Biotechnology industry.
Is Creative Medical Technology Holdings' Debt-to-Equity too high?
Creative Medical Technology Holdings' current Debt-to-Equity is 0.00. Based on the distribution chart, Creative Medical Technology Holdings ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Debt-to-Equity compare to MLEC and DRMA?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #999999 out of 965 companies for Debt-to-Equity. This places Creative Medical Technology Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.49, compared to a current price of $1.10 — trading 124.5% above its estimated fair value. The current Debt-to-Equity is 0.00. Creative Medical Technology Holdings' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $1.10 is trading 124.5% above its estimated GF Value™ of $0.49.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
Debt-to-Equity: 0.00
GF Value™: $0.49 vs. price of $1.10 (124.5% above fair value)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
28GF Score
Get the complete analysis for CELZ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
